The activity of CDK4/6 inhibitors in early breast cancer is not limited to Verzenio. Kisqali also presented data on adjuvant therapy after successful surgery at ASCO held in June. Although they are the same class of drugs, the clinical designs of the two drugs in early breast cancer are different in many ways. First, Verzenio was targeted for high-risk patients with lymph node metastasis. On the other hand, Kisqali did not limit the presence of lymph node metastases. Relatively less risky patient groups were also included in the clinical trial. The dose and duration of administration are also different. Verzenio uses the same dose as for metastatic breast cancer, and after two years of administration, only endocrine ther